AMRN – Amarin Corp ADR

AMRN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.5

Margin Of Safety %

-17

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.06

EPS Last/This Y

-0.87

EPS This/Next Y

0.01

Price

11.83

Target Price

12.5

Analyst Recom

Performance Q

-14.63

Upside

-485.9%

Beta

0.82

Ticker: AMRN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	AMRN	13.195	0.44	0.06	2319
2026-09-29	AMRN	13.16	0.44	0.32	2257
2026-09-30	AMRN	13.05	0.44	0.14	2266
2026-10-01	AMRN	12.72	0.43	0.24	2340
2026-10-02	AMRN	12.41	0.41	0.54	2423
2026-10-05	AMRN	12.09	0.41	0.00	2459
2026-10-06	AMRN	12.01	0.41	4.00	2464
2026-10-07	AMRN	12.05	0.45	0.00	2542
2026-10-08	AMRN	11.97	0.44	0.08	2583
2026-10-09	AMRN	12.02	0.43	0.02	2602
2026-10-12	AMRN	11.52	0.43	0.16	2635
2026-10-13	AMRN	11.56	0.40	0.18	2790
2026-10-14	AMRN	11.56	0.36	0.00	3040
2026-10-15	AMRN	11.61	0.36	0.00	3040
2026-10-16	AMRN	11.32	0.29	0.08	2945
2026-10-19	AMRN	11.53	0.19	0.00	2668
2026-10-20	AMRN	11.53	0.19	0.00	2718
2026-10-21	AMRN	11.54	0.18	0.01	2841
2026-10-22	AMRN	11.59	0.17	0.11	2894
2026-10-23	AMRN	11.81	0.17	0.18	2910
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-28	AMRN	13.24	-	-	-0.07
2026-09-29	AMRN	13.16	-	-	-0.07
2026-09-30	AMRN	13.02	-	-	-0.07
2026-10-01	AMRN	12.72	-	-	-0.07
2026-10-02	AMRN	12.31	-	-	-0.07
2026-10-05	AMRN	12.10	-	-	-0.07
2026-10-06	AMRN	12.05	-	-	-0.07
2026-10-07	AMRN	12.02	-	-	-0.07
2026-10-08	AMRN	12.00	-	-	-0.07
2026-10-09	AMRN	12.03	-	-	-0.07
2026-10-12	AMRN	11.52	-	-	-0.07
2026-10-13	AMRN	11.53	-	-	-0.07
2026-10-14	AMRN	11.60	-	-	-0.07
2026-10-15	AMRN	11.57	-	-	-0.07
2026-10-16	AMRN	11.32	-	-	-0.07
2026-10-19	AMRN	11.51	-	-	-0.07
2026-10-20	AMRN	11.51	-	-	-0.07
2026-10-21	AMRN	11.49	-	-	-0.07
2026-10-22	AMRN	11.58	-	-	-0.07
2026-10-23	AMRN	11.83	-	-	-0.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-28	AMRN	0	0.10	2.49
2026-09-29	AMRN	0	0.10	2.49
2026-09-30	AMRN	0	0.10	2.49
2026-10-01	AMRN	0	0.10	2.49
2026-10-02	AMRN	0	0.10	2.49
2026-10-05	AMRN	0	0.08	2.49
2026-10-06	AMRN	0	0.08	2.49
2026-10-07	AMRN	0	0.08	2.49
2026-10-08	AMRN	0	0.08	2.49
2026-10-09	AMRN	0	0.08	2.49
2026-10-12	AMRN	0	0.08	2.50
2026-10-13	AMRN	0	0.08	2.50
2026-10-14	AMRN	0.00	0.08	2.50
2026-10-15	AMRN	0.00	0.08	2.50
2026-10-16	AMRN	0.00	0.08	2.50
2026-10-19	AMRN	0.00	0.04	2.50
2026-10-20	AMRN	0.00	0.04	2.50
2026-10-21	AMRN	0.00	0.04	2.50
2026-10-22	AMRN	0.00	0.04	2.50
2026-10-23	AMRN	0.00	0.04	2.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.02

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

Institutional Transactions

0.04

Beta

0.82

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

9.86

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.2

Max Drawdown 5-Year %

-92

Target Price

12.5

P/E

Forward P/E

PEG

P/S

1.34

P/B

0.56

P/Free Cash Flow

16.01

EPS

-1.3

Average EPS Est. Cur. Y

-0.07

EPS Next Y. (Est.)

-0.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.57

Relative Volume

1.26

Return on Equity vs Sector %

-31.7

Return on Equity vs Industry %

-41.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

◆ AMRN Healthcare

$11.79

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

18/25

Volume

4/15

Valuation

8/20

TP/AR

0/10

Options

7/10

RSI

36.8

Range 1M

21.4%

Sup Dist

3.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

13/30

Estimates

1/20

Inst/Vol

4/15

Options

10/10

EPS Yr

-565.5%

EPS NY

42.6%

52W%

5.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -7.4% upside

Quality

5/30

Valuation

3/30

Growth

12/25

Stability

7/10

LT Trend

1/5

Upside

-7.4%

Quality

MoS

-17%

AMRN — P/E HistoricalBiotechnology

Amarin Corporation plc

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 80

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN

Latest News

—

Caricamento notizie per AMRN…

stock quote shares AMRN – Amarin Corp ADR Stock Price stock today

news today AMRN – Amarin Corp ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRN – Amarin Corp ADR yahoo finance google finance

stock history AMRN – Amarin Corp ADR invest stock market

stock prices AMRN premarket after hours

ticker AMRN fair value insiders trading

GRFS – Grifols, S.A.

GRFS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.34

Margin Of Safety %

Put/Call OI Ratio

0.73

EPS Next Q Diff

EPS Last/This Y

0.5

EPS This/Next Y

0.28

Price

7.54

Target Price

12.93

Analyst Recom

2.25

Performance Q

Upside

N/A

Beta

0.67

Ticker: GRFS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	GRFS	7.41	0.84	4.00	5885
2026-09-29	GRFS	7.3	0.84	4.00	5885
2026-09-30	GRFS	7.31	0.84	4.00	5892
2026-10-01	GRFS	7.3	0.84	0.20	5892
2026-10-02	GRFS	7.3	0.85	999.99	5900
2026-10-05	GRFS	7.41	0.85	0.00	5900
2026-10-06	GRFS	7.53	0.85	1.14	5893
2026-10-07	GRFS	7.49	0.87	0.00	5898
2026-10-08	GRFS	7.4	0.87	0.00	5899
2026-10-09	GRFS	7.45	0.87	0.00	5899
2026-10-12	GRFS	7.36	0.81	3.60	6158
2026-10-13	GRFS	7.19	0.81	0.04	6170
2026-10-14	GRFS	7.24	0.81	0.04	6157
2026-10-15	GRFS	7.54	0.80	0.00	6215
2026-10-16	GRFS	7.65	0.80	0.13	6215
2026-10-19	GRFS	7.62	0.79	0.00	6259
2026-10-20	GRFS	7.53	0.77	0.00	6311
2026-10-21	GRFS	7.51	0.77	0.00	6312
2026-10-22	GRFS	7.45	0.77	0.00	6312
2026-10-23	GRFS	7.55	0.73	0.00	6540
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-28	GRFS	7.41	-	-	1.16
2026-09-29	GRFS	7.30	-	-	1.16
2026-09-30	GRFS	7.30	-	-	1.16
2026-10-01	GRFS	7.30	-	-	1.16
2026-10-02	GRFS	7.31	-	-	1.16
2026-10-05	GRFS	7.42	-	-	1.16
2026-10-06	GRFS	7.54	-	-	1.16
2026-10-07	GRFS	7.50	-	-	1.16
2026-10-08	GRFS	7.39	-	-	1.16
2026-10-09	GRFS	7.45	-	-	1.16
2026-10-12	GRFS	7.36	-	-	1.16
2026-10-13	GRFS	7.20	-	-	1.16
2026-10-14	GRFS	7.24	-	-	1.16
2026-10-15	GRFS	7.54	-	-	1.16
2026-10-16	GRFS	7.63	-	-	1.16
2026-10-19	GRFS	7.63	-	-	1.16
2026-10-20	GRFS	7.63	-	-	1.16
2026-10-21	GRFS	7.54	-	-	1.16
2026-10-22	GRFS	7.45	-	-	1.16
2026-10-23	GRFS	7.54	-	-	1.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.3

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

Institutional Transactions

-2.53

Beta

0.67

Average Sales Estimate Current Quarter

1969

Average Sales Estimate Next Quarter

2170

Fair Value

10.13

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-60.6

Target Price

12.93

P/E

10.23

Forward P/E

6.49

PEG

0.28

P/S

0.24

P/B

0.85

P/Free Cash Flow

2.17

EPS

0.77

Average EPS Est. Cur. Y

1.16

EPS Next Y. (Est.)

1.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

6.09

Relative Volume

0.35

Return on Equity vs Sector %

-17.5

Return on Equity vs Industry %

-27

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for GRFS

GRFS — P/E HistoricalDrug Manufacturers - General

Grifols, S.A.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 25258

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS

Latest News

—

Caricamento notizie per GRFS…

stock quote shares GRFS – Grifols, S.A. Stock Price stock today

news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025

marketwatch GRFS – Grifols, S.A. yahoo finance google finance

stock history GRFS – Grifols, S.A. invest stock market

stock prices GRFS premarket after hours

ticker GRFS fair value insiders trading

SNY – Sanofi

SNY — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.45

Margin Of Safety %

Put/Call OI Ratio

0.76

EPS Next Q Diff

-0.09

EPS Last/This Y

1.34

EPS This/Next Y

0.35

Price

41.59

Target Price

49.8

Analyst Recom

2.1

Performance Q

-5.45

Upside

-39.4%

Beta

0.29

Ticker: SNY

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	SNY	41.18	0.80	0.09	85917
2026-09-29	SNY	40.74	0.78	0.46	86899
2026-09-30	SNY	41.23	0.78	0.23	87380
2026-10-01	SNY	40.65	0.78	0.53	87815
2026-10-02	SNY	39.92	0.77	1.15	88697
2026-10-05	SNY	39.52	0.78	0.66	90332
2026-10-06	SNY	39.56	0.77	0.46	91513
2026-10-07	SNY	40.21	0.75	1.08	93141
2026-10-08	SNY	40.22	0.76	1.10	93444
2026-10-09	SNY	40.08	0.75	0.78	93685
2026-10-12	SNY	39.75	0.75	1.34	93899
2026-10-13	SNY	39.1	0.74	1.65	93979
2026-10-14	SNY	39.76	0.73	0.31	93976
2026-10-15	SNY	40.29	0.73	4.81	94057
2026-10-16	SNY	40.59	0.75	0.20	95155
2026-10-19	SNY	39.57	0.79	0.19	90530
2026-10-20	SNY	41.4	0.78	0.57	92592
2026-10-21	SNY	40.97	0.78	2.28	93108
2026-10-22	SNY	41.95	0.78	0.24	93302
2026-10-23	SNY	41.58	0.76	0.26	94600
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-28	SNY	41.18	-8.0	554.2	5.02
2026-09-29	SNY	40.76	-8.0	501.2	5.02
2026-09-30	SNY	41.23	-8.0	639.6	5.02
2026-10-01	SNY	40.65	-8.0	497.3	5.02
2026-10-02	SNY	39.92	-8.0	503.8	5.02
2026-10-05	SNY	39.52	-8.0	386.6	5.02
2026-10-06	SNY	39.58	-8.0	580.5	5.02
2026-10-07	SNY	40.21	-8.0	667.2	5.02
2026-10-08	SNY	40.23	-8.0	558.3	5.02
2026-10-09	SNY	40.07	-8.0	537.2	5.02
2026-10-12	SNY	39.74	-10.7	488.5	4.93
2026-10-13	SNY	39.08	-8.1	459.7	4.95
2026-10-14	SNY	39.76	-10.7	638.2	4.93
2026-10-15	SNY	40.28	-10.7	560.7	4.93
2026-10-16	SNY	40.61	-10.7	570.6	4.93
2026-10-19	SNY	39.55	-10.7	351.6	4.93
2026-10-20	SNY	39.55	-10.7	351.6	4.93
2026-10-21	SNY	41.40	-10.7	813.9	4.93
2026-10-22	SNY	41.96	-10.7	672.8	4.93
2026-10-23	SNY	41.59	-10.7	471.4	4.93
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-28	SNY	0	-0.09	0.39
2026-09-29	SNY	0	-0.09	0.39
2026-09-30	SNY	0	-0.09	0.39
2026-10-01	SNY	0	-0.09	0.39
2026-10-02	SNY	0	-0.09	0.39
2026-10-05	SNY	0	-0.48	0.39
2026-10-06	SNY	0	-0.48	0.39
2026-10-07	SNY	0	-0.48	0.39
2026-10-08	SNY	0	-0.48	0.39
2026-10-09	SNY	0	-0.48	0.39
2026-10-12	SNY	0	-0.37	0.45
2026-10-13	SNY	0	-0.37	0.45
2026-10-14	SNY	0	-0.37	0.45
2026-10-15	SNY	0	-0.37	0.45
2026-10-16	SNY	0	-0.37	0.45
2026-10-19	SNY	0	-0.55	0.45
2026-10-20	SNY	0	-0.55	0.45
2026-10-21	SNY	0	-0.55	0.45
2026-10-22	SNY	0	-0.55	0.45
2026-10-23	SNY	0	-0.55	0.45
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.21

Avg. EPS Est. Current Quarter

1.51

Avg. EPS Est. Next Quarter

1.12

Insider Transactions

Institutional Transactions

-0.55

Beta

0.29

Average Sales Estimate Current Quarter

13186

Average Sales Estimate Next Quarter

12787

Fair Value

51.63

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

30.8

Max Drawdown 5-Year %

-33.5

Target Price

49.8

P/E

21.43

Forward P/E

8.08

PEG

1.36

P/S

1.85

P/B

1.28

P/Free Cash Flow

8.23

EPS

1.94

Average EPS Est. Cur. Y

4.93

EPS Next Y. (Est.)

5.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.78

Relative Volume

0.67

Return on Equity vs Sector %

-19.9

Return on Equity vs Industry %

-29.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.08

EBIT Estimation

471.4

◆ SNY Healthcare

$41.60

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

13/25

Volume

6/15

Valuation

16/20

TP/AR

1/10

Options

3/10

RSI

53.4

Range 1M

79.8%

Sup Dist

0.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

9/30

Estimates

5/20

Inst/Vol

0/15

Options

7/10

EPS Yr

3.5%

EPS NY

6.6%

52W%

17.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +43.7% upside

Quality

10/30

Valuation

20/30

Growth

8/25

Stability

3/10

LT Trend

1/5

Upside

+43.7%

Quality

MoS

24%

SNY — P/E HistoricalDrug Manufacturers - General

Sanofi

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 74846

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

SNY

Latest News

—

Caricamento notizie per SNY…

stock quote shares SNY – Sanofi Stock Price stock today

news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025

marketwatch SNY – Sanofi yahoo finance google finance

stock history SNY – Sanofi invest stock market

stock prices SNY premarket after hours

ticker SNY fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.95

Margin Of Safety %

Put/Call OI Ratio

0.69

EPS Next Q Diff

-0.31

EPS Last/This Y

-0.57

EPS This/Next Y

0.08

Price

39.03

Target Price

49.66

Analyst Recom

Performance Q

-21.43

Upside

36.2%

Beta

0.72

Ticker: NVO

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	NVO	38.72	0.63	1.35	1427824
2026-09-29	NVO	38.31	0.64	0.56	1455381
2026-09-30	NVO	37.92	0.64	0.72	1475341
2026-10-01	NVO	37.41	0.65	1.64	1505284
2026-10-02	NVO	37.3	0.62	1.12	1497540
2026-10-05	NVO	37.53	0.64	1.02	1478251
2026-10-06	NVO	37.53	0.64	0.49	1497108
2026-10-07	NVO	38.26	0.64	0.36	1505171
2026-10-08	NVO	38.16	0.63	0.44	1523176
2026-10-09	NVO	38.63	0.62	0.37	1541091
2026-10-12	NVO	38.58	0.63	0.52	1525514
2026-10-13	NVO	38.06	0.63	0.47	1536811
2026-10-14	NVO	38.12	0.63	0.86	1541320
2026-10-15	NVO	39.24	0.63	0.80	1547006
2026-10-16	NVO	38.81	0.63	0.56	1550654
2026-10-19	NVO	38.41	0.64	1.86	1381743
2026-10-20	NVO	39.34	0.68	0.48	1433087
2026-10-21	NVO	39.07	0.68	1.36	1450808
2026-10-22	NVO	39.44	0.69	0.53	1472515
2026-10-23	NVO	39.03	0.69	0.64	1481126
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-28	NVO	38.72	11.2	-5252.6	22.75
2026-09-29	NVO	38.31	11.2	-5352.5	3.46
2026-09-30	NVO	37.90	11.2	-3716.9	3.45
2026-10-01	NVO	37.41	11.2	-3811.2	3.45
2026-10-02	NVO	37.30	11.2	-3819.0	3.43
2026-10-05	NVO	37.55	11.2	-3540.1	3.42
2026-10-06	NVO	37.53	7.8	-3266.5	3.41
2026-10-07	NVO	38.26	7.8	-2954.9	3.42
2026-10-08	NVO	38.15	7.2	-2884.1	3.40
2026-10-09	NVO	38.62	7.2	-3286.7	3.40
2026-10-12	NVO	38.55	7.2	-3018.7	3.38
2026-10-13	NVO	38.03	7.2	-3605.3	3.37
2026-10-14	NVO	38.13	2.7	-3425.3	3.34
2026-10-15	NVO	39.23	2.7	-2966.2	3.34
2026-10-16	NVO	38.82	2.7	-3670.4	3.37
2026-10-19	NVO	38.42	2.7	-3637.8	3.37
2026-10-20	NVO	38.42	2.7	-3637.8	3.37
2026-10-21	NVO	39.35	2.7	-3018.1	3.36
2026-10-22	NVO	39.45	2.7	-3333.2	3.36
2026-10-23	NVO	39.03	2.7	-3675.3	3.36
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-28	NVO	0.00	-0.41	0.79
2026-09-29	NVO	0.00	-0.41	0.79
2026-09-30	NVO	0.00	-0.41	0.79
2026-10-01	NVO	0.00	-0.41	0.79
2026-10-02	NVO	0.00	-0.41	0.79
2026-10-05	NVO	0.00	-0.49	0.79
2026-10-06	NVO	0.00	-0.49	0.79
2026-10-07	NVO	0.00	-0.49	0.79
2026-10-08	NVO	0.00	-0.49	0.79
2026-10-09	NVO	0.00	-0.49	0.79
2026-10-12	NVO	0.00	-0.47	0.95
2026-10-13	NVO	0.00	-0.47	0.95
2026-10-14	NVO	0.00	-0.47	0.95
2026-10-15	NVO	0.00	-0.47	0.95
2026-10-16	NVO	0.00	-0.47	0.95
2026-10-19	NVO	0.00	-0.06	0.95
2026-10-20	NVO	0.00	-0.06	0.95
2026-10-21	NVO	0.00	-0.06	0.95
2026-10-22	NVO	0.00	-0.06	0.95
2026-10-23	NVO	0.00	-0.06	0.95
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.96

Avg. EPS Est. Current Quarter

0.69

Avg. EPS Est. Next Quarter

0.65

Insider Transactions

Institutional Transactions

-0.06

Beta

0.72

Average Sales Estimate Current Quarter

11061

Average Sales Estimate Next Quarter

11435

Fair Value

39.36

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

73.7

Max Drawdown 5-Year %

-74.7

Target Price

49.66

P/E

9.54

Forward P/E

11.77

PEG

P/S

2.54

P/B

5.1

P/Free Cash Flow

11.07

EPS

4.09

Average EPS Est. Cur. Y

3.36

EPS Next Y. (Est.)

3.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.36

Relative Volume

0.7

Return on Equity vs Sector %

Return on Equity vs Industry %

17.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.13

EBIT Estimation

-3675.3

◆ NVO Healthcare

$39.03

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

13/20

Pullback

9/25

Volume

9/15

Valuation

20/20

TP/AR

0/10

Options

6/10

RSI

45.5

Range 1M

69.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

4/30

Estimates

6/20

Inst/Vol

0/15

Options

7/10

EPS Yr

-8.1%

EPS NY

-0.9%

52W%

13%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +13% upside

Quality

24/30

Valuation

9/30

Growth

5/25

Stability

3/10

LT Trend

4/5

Upside

+13%

Quality

MoS

NVO — P/E HistoricalDrug Manufacturers - General

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 66700

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

OGN – Organon & Co.

OGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

7.27

Margin Of Safety %

Put/Call OI Ratio

1.58

EPS Next Q Diff

-0.13

EPS Last/This Y

-0.24

EPS This/Next Y

0.2

Price

13.76

Target Price

Analyst Recom

Performance Q

1.59

Upside

24.7%

Beta

1.53

Ticker: OGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	OGN	13.73	1.60	0.78	90079
2026-09-29	OGN	13.74	1.60	0.05	90152
2026-09-30	OGN	13.71	1.60	0.22	90283
2026-10-01	OGN	13.72	1.59	0.08	90464
2026-10-02	OGN	13.73	1.59	0.11	90475
2026-10-05	OGN	13.72	1.59	0.08	90478
2026-10-06	OGN	13.74	1.59	0.05	90463
2026-10-07	OGN	13.79	1.59	0.03	90524
2026-10-08	OGN	13.76	1.58	0.01	90636
2026-10-09	OGN	13.81	1.55	0.15	91502
2026-10-12	OGN	13.77	1.53	0.13	91960
2026-10-13	OGN	13.77	1.52	0.39	92255
2026-10-14	OGN	13.74	1.51	0.00	92567
2026-10-15	OGN	13.77	1.50	0.08	92808
2026-10-16	OGN	13.76	1.48	0.00	93313
2026-10-19	OGN	13.74	1.60	0.64	79573
2026-10-20	OGN	13.76	1.60	0.87	79602
2026-10-21	OGN	13.74	1.59	0.45	80424
2026-10-22	OGN	13.74	1.58	0.20	80777
2026-10-23	OGN	13.76	1.58	5.59	80789
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-28	OGN	13.73	-8.3	-	3.34
2026-09-29	OGN	13.75	-8.3	-	3.34
2026-09-30	OGN	13.71	-8.3	-	3.34
2026-10-01	OGN	13.72	-8.3	-	3.34
2026-10-02	OGN	13.72	-8.3	-	3.34
2026-10-05	OGN	13.71	-12.6	-	3.34
2026-10-06	OGN	13.75	-12.6	-	3.34
2026-10-07	OGN	13.79	-12.6	-	3.34
2026-10-08	OGN	13.76	-12.6	-	3.34
2026-10-09	OGN	13.81	-12.6	-	3.34
2026-10-12	OGN	13.77	-12.6	-	3.34
2026-10-13	OGN	13.77	-12.6	-	3.34
2026-10-14	OGN	13.74	-12.6	-	3.34
2026-10-15	OGN	13.77	-12.6	-	3.34
2026-10-16	OGN	13.75	-12.6	-	3.34
2026-10-19	OGN	13.74	-12.6	-	3.34
2026-10-20	OGN	13.74	-12.6	-	3.34
2026-10-21	OGN	13.76	-12.6	-	3.34
2026-10-22	OGN	13.74	-7.2	-	3.42
2026-10-23	OGN	13.76	-7.2	-	3.42
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-28	OGN	0.70	0.10	6.72
2026-09-29	OGN	0.70	0.10	6.72
2026-09-30	OGN	0.70	0.10	6.72
2026-10-01	OGN	0.70	0.10	6.72
2026-10-02	OGN	0.70	0.10	6.72
2026-10-05	OGN	0.70	-0.16	6.72
2026-10-06	OGN	0.70	-0.16	6.72
2026-10-07	OGN	0.70	-0.16	6.72
2026-10-08	OGN	0.70	-0.16	6.72
2026-10-09	OGN	0.70	-0.16	6.72
2026-10-12	OGN	0.70	0.20	7.27
2026-10-13	OGN	0.70	0.20	7.27
2026-10-14	OGN	0.70	0.20	7.27
2026-10-15	OGN	0.70	0.20	7.27
2026-10-16	OGN	0.70	0.20	7.27
2026-10-19	OGN	0.70	-0.17	7.27
2026-10-20	OGN	0.70	-0.17	7.27
2026-10-21	OGN	0.70	-0.17	7.27
2026-10-22	OGN	0.70	-0.17	7.27
2026-10-23	OGN	0.70	-0.17	7.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.8

Avg. EPS Est. Current Quarter

0.94

Avg. EPS Est. Next Quarter

0.67

Insider Transactions

0.7

Institutional Transactions

-0.17

Beta

1.53

Average Sales Estimate Current Quarter

1584

Average Sales Estimate Next Quarter

1551

Fair Value

18.11

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

65.2

Max Drawdown 5-Year %

-82.7

Target Price

P/E

17.62

Forward P/E

3.79

PEG

1.23

P/S

0.59

P/B

3.59

P/Free Cash Flow

6.37

EPS

0.78

Average EPS Est. Cur. Y

3.42

EPS Next Y. (Est.)

3.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.41

Relative Volume

0.39

Return on Equity vs Sector %

-4.8

Return on Equity vs Industry %

-14.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

◆ OGN Healthcare

$13.76

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

8/20

Pullback

15/25

Volume

11/15

Valuation

11/20

TP/AR

2/10

Options

2/10

RSI

53.8

Range 1M

42.3%

Sup Dist

0.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

1/30

Estimates

5/20

Inst/Vol

2/15

Options

3/10

EPS Yr

-8.5%

EPS NY

8.4%

52W%

99.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +249.2% upside

Quality

12/30

Valuation

26/30

Growth

3/25

Stability

5/10

LT Trend

1/5

Upside

+249.2%

Quality

MoS

32%

OGN — P/E HistoricalDrug Manufacturers - General

Organon & Co.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 10000

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

OGN

Latest News

—

Caricamento notizie per OGN…

stock quote shares OGN – Organon & Co. Stock Price stock today

news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGN – Organon & Co. yahoo finance google finance

stock history OGN – Organon & Co. invest stock market

stock prices OGN premarket after hours

ticker OGN fair value insiders trading

HZNP – Horizon Therapeutics Public Limited Company

HZNP — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.11

Margin Of Safety %

-6

Put/Call OI Ratio

EPS Next Q Diff

0.02

EPS Last/This Y

EPS This/Next Y

0.18

Price

116.3

Target Price

116.5

Analyst Recom

Performance Q

13.24

Upside

N/A

Beta

1.01

Ticker: HZNP

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-28	HZNP	116.3	N/A	N/A	0
2026-09-29	HZNP	116.3	N/A	N/A	0
2026-09-30	HZNP	116.3	N/A	N/A	0
2026-10-01	HZNP	116.3	N/A	N/A	0
2026-10-02	HZNP	116.3	N/A	N/A	0
2026-10-05	HZNP	116.3	N/A	N/A	0
2026-10-06	HZNP	116.3	N/A	N/A	0
2026-10-07	HZNP	116.3	N/A	N/A	0
2026-10-08	HZNP	116.3	N/A	N/A	0
2026-10-09	HZNP	116.3	N/A	N/A	0
2026-10-12	HZNP	116.3	N/A	N/A	0
2026-10-13	HZNP	116.3	N/A	N/A	0
2026-10-14	HZNP	116.3	N/A	N/A	0
2026-10-15	HZNP	116.3	N/A	N/A	0
2026-10-16	HZNP	116.3	N/A	N/A	0
2026-10-19	HZNP	116.3	N/A	N/A	0
2026-10-20	HZNP	116.3	N/A	N/A	0
2026-10-21	HZNP	116.3	N/A	N/A	0
2026-10-22	HZNP	116.3	N/A	N/A	0
2026-10-23	HZNP	116.3	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.22

Avg. EPS Est. Next Quarter

1.4

Insider Transactions

Institutional Transactions

1.83

Beta

1.01

Average Sales Estimate Current Quarter

954

Average Sales Estimate Next Quarter

1040

Fair Value

109.22

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.5

Max Drawdown 5-Year %

-50.9

Target Price

116.5

P/E

62.16

Forward P/E

18.11

PEG

12.43

P/S

7.31

P/B

5.01

P/Free Cash Flow

27.79

EPS

1.87

Average EPS Est. Cur. Y

4.64

EPS Next Y. (Est.)

5.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.02

Relative Volume

Return on Equity vs Sector %

-13.1

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1038.8

No data found for HZNP

HZNP — P/E HistoricalDrug Manufacturers - General

HZNP

Latest News

—

Caricamento notizie per HZNP…

stock quote shares HZNP – Horizon Therapeutics Public Limited Company Stock Price stock today

news today HZNP – Horizon Therapeutics Public Limited Company stock forecast ,stock prediction 2023 2024 2025

marketwatch HZNP – Horizon Therapeutics Public Limited Company yahoo finance google finance

stock history HZNP – Horizon Therapeutics Public Limited Company invest stock market

stock prices HZNP premarket after hours

ticker HZNP fair value insiders trading

No more stocks to show

AMRN – Amarin Corp ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

GRFS – Grifols, S.A.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GRFS

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y